News
![2 Big-Name Stocks Are Falling Wednesday -- Here's Why: https://g.foolcdn.com/editorial/images/758168/vaccine-gettyimages-1298099807.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeGJ4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--279d6d49a1812a424f9480a1470f69615de208e7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/vaccine-gettyimages-1298099807.jpg?locale=us)
2 Big-Name Stocks Are Falling Wednesday -- Here's Why
The stock market looked ready to keep climbing early Wednesday, even as investors were largely in wait-and-see mode during the last day of the Federal Reserve's current monetary policy meeting
![Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?: https://g.foolcdn.com/editorial/images/758050/biotech.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK2Z3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3301ad3b969e64e4dee3a469914655ad6d05c30b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/biotech.jpg?locale=us)
Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?
Outperforming the benchmark S&P 500 index over a long period is a formidable challenge. This task becomes even more daunting when choosing stocks from the healthcare sector, where the competitive
![AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors: https://g.foolcdn.com/editorial/images/757505/investor-thinks-while-looking-out-a-window.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN3p2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7522171c0efe67bb080283ac70964a6a596ae48b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-thinks-while-looking-out-a-window.jpg?locale=us)
AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors
With AbbVie (NYSE: ABBV) reporting on Nov. 30 that it plans to acquire ImmunoGen, (NASDAQ: IMGN) a biotech developing antibody-drug conjugate (ADC) therapies for various cancers, it's clear that the
![Humana Earns Top Score in Human Rights Campaign Foundation’s 2023 Corporate Equality Index: https://mms.businesswire.com/media/20231212562749/en/1965827/5/IMG_6807.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNG52YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ed24146a91d2c0712c59353b8b50e62690e922c7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/IMG_6807.jpg?locale=us)
Humana Earns Top Score in Human Rights Campaign Foundation’s 2023 Corporate Equality Index
Leading US health insurer and health care services company Humana Inc. (NYSE: HUM) has earned a score of 100 percent on the Human Rights Campaign Foundation Corporate Equality Index and the
![3 Dirt Cheap Stocks That Make Terrific Buys Before the End of the Year: https://g.foolcdn.com/editorial/images/757804/gettyimages-1027653456.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL3Z1YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4bd2f3e2d5654752a8a7b33a9019794894e63b99/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1027653456.jpg?locale=us)
3 Dirt Cheap Stocks That Make Terrific Buys Before the End of the Year
The stock market has climbed this year, but that doesn't mean the bargains are over. Many stocks missed out on the rally even though their long-term outlooks remain solid. And these are the stocks
![EQS-News: Carl Zeiss Meditec increased revenue in fiscal year 2022/23 by around 10 percenthttp://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBHUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--30a4f87e2f6442a34d491960296cefece4f65ecc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/carl_zeiss_meditec_logogif.png?locale=us)
EQS-News: Carl Zeiss Meditec increased revenue in fiscal year 2022/23 by around 10 percent
![Why Cigna Stock Soared Today: https://g.foolcdn.com/editorial/images/757901/mergers-and-acquisitions-chess-board-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNTd1YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8111a9f8919de956bf8c9b9f42ee9a267e1d1b77/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/mergers-and-acquisitions-chess-board-1.jpg?locale=us)
Why Cigna Stock Soared Today
Shares of Cigna Group (NYSE: CI) were up 16.6% as of 1:30 p.m. ET Monday after the health insurance giant reportedly called off its potential acquisition Humana and announced a $10 billion buyback
![Monday Morning's 2 Must-Watch Stocks: https://g.foolcdn.com/editorial/images/757874/shopping-3-people-gettyimages-bldhs040056tgs.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMVB1YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--98730d70bc7750bfeb04a3e1cbf902569c552b8e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/shopping-3-people-gettyimages-bldhs040056tgs.jpg?locale=us)
Monday Morning's 2 Must-Watch Stocks
The stock market has been on a tear for more than a month now, and so it's not unreasonable to see major market benchmarks taking a pause coming into a new week. Stock indexes were mostly flat at
![This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks: https://g.foolcdn.com/editorial/images/757221/scientist-peers-into-microscope-in-laboratory.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM1R0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--88e38f3587585f642b96d07ad7682360b9ab7446/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientist-peers-into-microscope-in-laboratory.jpg?locale=us)
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
On Nov. 28, the Food and Drug Administration (FDA) announced that it was opening an investigation into the possibility of previously unknown serious safety risks associated with the hottest and most
![AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?: https://g.foolcdn.com/editorial/images/757523/two-investors-meet-and-discuss.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMUh0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--214a19a77d6dd8950e7c78ed6562edd8bdfd71cc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-investors-meet-and-discuss.jpg?locale=us)
AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?
It's hard to see a presentation or read a press release by a major pharmaceutical company these days without hearing about how they're planning to use artificial intelligence (AI) to supercharge
![Is Now the Right Time to Buy AstraZeneca Stock?: https://g.foolcdn.com/editorial/images/757516/two-investors-consult-papers-and-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGJ0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--119b276d95633d632f88ee89e7a01601a4302bc6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-investors-consult-papers-and-laptop.jpg?locale=us)
Is Now the Right Time to Buy AstraZeneca Stock?
With shares of AstraZeneca (NASDAQ: AZN) returning 55% over the last three years, easily topping the market's return of 29%, it's no surprise why investors might be curious about whether there's
![AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?: https://g.foolcdn.com/editorial/images/757593/big-fish-eating-little-fish.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeHp0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e01c1ac3cef4469a583fd7342610779797912f3d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/big-fish-eating-little-fish.jpg?locale=us)
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?
Change the narrative: That's been a classic strategy for businesses facing stiff challenges. And it's a strategy that AbbVie (NYSE: ABBV) appears to have pulled off successfully in recent days.
![Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?: https://g.foolcdn.com/editorial/images/757762/scientists-high-five-smile.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUR0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a54aa343b4683e2163d9cb5f9cd52add5fdbb622/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-high-five-smile.jpg?locale=us)
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) has built a billion-dollar cystic fibrosis (CF) treatment empire, but investors have been looking for something more. They've hoped to see the company broaden
![2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond: https://g.foolcdn.com/editorial/images/756670/person-working-in-a-cannabis-dispensary.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1R0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--70fc4eaa675c411714a84185be2b810286dbc4aa/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-working-in-a-cannabis-dispensary.jpg?locale=us)
2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond
One famous investing maxim advises to buy low and sell high. That's sage advice, but not all stocks are worth investing in while they are down. If they don't go up, you won't have profited from the
![3 Dividend Stocks Trading at 52-Week Lows: https://g.foolcdn.com/editorial/images/757729/gettyimages-1305501354.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0RzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--507edb15b88abc7856c35e55e4a93feb2b8aa063/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1305501354.jpg?locale=us)
3 Dividend Stocks Trading at 52-Week Lows
I have always stated that stocks should not be bought just because they trade at a 52-week low. A new 52-week low does not make a particular stock cheap.
In today's video I will look at three
![2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years: https://g.foolcdn.com/editorial/images/757244/businesswoman-celebrating-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0hzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--68d4a85e2930bf3f997f9b9033fcdb2f8d9a2ffd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/businesswoman-celebrating-1.jpg?locale=us)
2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years
While some stocks may not be attracting quite the same hype they were a few years ago, that doesn't mean the quality of their underlying businesses has evaporated. If your intention is to own great
![Is Pfizer Stock a Buy Now?: https://g.foolcdn.com/editorial/images/756932/businessman-with-a-chart-looking-at-his-computer.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0hzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5759f679ffc52a61d932c6664738069c605edb0a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/businessman-with-a-chart-looking-at-his-computer.jpg?locale=us)
Is Pfizer Stock a Buy Now?
Shares of Pfizer (NYSE: PFE) have been in an endless tailspin this year -- now down more than 40%. The top drugmaker can't seem to catch a break. Revenue from its COVID-19 products is down big, and
![Could Sarepta Therapeutics Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/756930/gettyimages-1016186674.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK2ZzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--768e2b757f5eddf0c7e2cf4a3b4a87b8aaff3ba4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1016186674.jpg?locale=us)
Could Sarepta Therapeutics Stock Help You Become a Millionaire?
Sarepta Therapeutics (NASDAQ: SRPT) is a mid-cap stock that has the potential to be a big player in the gene therapy market -- at least, so the business and its investors hope. It has made for a
![3 Dividend Stocks You Can Safely Hold for Decades: https://g.foolcdn.com/editorial/images/757437/young-woman-smiling-hands-behind-head.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNzdzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b291eabd97cb4e8f3285f29ba11476f5c17b4a72/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/young-woman-smiling-hands-behind-head.jpg?locale=us)
3 Dividend Stocks You Can Safely Hold for Decades
Remember Montgomery Ward, Lehman Brothers, and Pan Am? They were all well-known publicly traded companies that paid dividends. And they all went out of business.
Investors who bought those stocks
![Better Dividend Stock: AbbVie vs. Medical Properties Trust: https://g.foolcdn.com/editorial/images/757643/investor-at-home-getty.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFBzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8a0e9eb8d610c4bef57cbeaf18961a4ea3e03bdb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-at-home-getty.jpg?locale=us)
Better Dividend Stock: AbbVie vs. Medical Properties Trust
Income-seeking investors have some interesting options to choose from in the healthcare sector right now. AbbVie (NYSE: ABBV), the pharmaceutical giant behind the top-selling drug of the past
![Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?: https://g.foolcdn.com/editorial/images/757218/chemist-team-looking-beaker-of-green-chemical.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMFBzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4d431282415dc0b1fbdbfd3911afb95369bdafb5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/chemist-team-looking-beaker-of-green-chemical.jpg?locale=us)
Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?
On Dec. 1, Pfizer (NYSE: PFE) reported some less-than-great news to investors. In short, its latest attempt at developing a drug to compete with Novo Nordisk's blockbuster medicine Ozempic will not
![2 Healthcare Stocks to Buy Hand Over Fist in December: https://g.foolcdn.com/editorial/images/757033/elderly-person-sitting-on-a-bed.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeHZzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9bbb14d42ec446eebcced5c9dcfdc747a20b6927/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/elderly-person-sitting-on-a-bed.jpg?locale=us)
2 Healthcare Stocks to Buy Hand Over Fist in December
As the year draws to a close, it's as good a time as any to review one's investments and consider adding more money into the stock market. The goal shouldn't be to take advantage of the January
![CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?: https://g.foolcdn.com/editorial/images/757216/chart-reflected-on-investor-glasses.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeURzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7ecd5cfae619a5a21b3d9fa5deb9316979343c8c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/chart-reflected-on-investor-glasses.jpg?locale=us)
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?
As reported by Fierce Biotech on Nov. 22, gene-therapy star CRISPR Therapeutics (NASDAQ: CRSP) laid off 10% of its employees shortly after reporting its Q3 earnings earlier in the month. Given that
![3 High-Yielding Dividend Stocks That Are Near Their 52-Week Lows: https://g.foolcdn.com/editorial/images/756927/a-person-smiling-and-reviewing-their-finances.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWpzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b4cda17c1288228555af86ec3cfe13539dae6abb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-person-smiling-and-reviewing-their-finances.jpg?locale=us)
3 High-Yielding Dividend Stocks That Are Near Their 52-Week Lows
Are you looking for some quality dividend stocks to buy right now? When it comes to investing, it's often a good idea to check out those that haven't been doing too well lately and are trading near
![Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/756929/rich-couple-on-a-boat.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd2pzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8be28c2f23f349f0251457c88a898604f87f9261/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/rich-couple-on-a-boat.jpg?locale=us)
Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?
Regeneron Pharmaceuticals (NASDAQ: REGN) is a top pharmaceutical company with many promising assets in its portfolio. Its diverse business has enabled the business to grow over the years. In the